Matsuoka Shuji

マツオカシュウジ | Matsuoka Shuji

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (3)： Cell Death , therapeutic monoclonal antibody , Immunology

Research theme for competitive and other funds (11)：

2022 - 2025 神経膠芽腫に対する新規個別化抗体療法の開発
2021 - 2024 Pathogenesis of hearing impairment through autoimmune reaction by Treg regulatory factor Helios mutations
2015 - 2018 Establishment of therapeutic mAbs for malignant lymphoma
2009 - 2011 Identification of initiating cells of lung adenocarcinoma, analysis of its characteristics and application to therapy of lung adenocarcinoma.
2004 - 2005 Molecular mechanism of hypercarcinogenic state -inflammation-induced hepatocarcinogenesis-

Show all

Papers (24)：

Natsuko Mizutani, Masaaki Abe, Kazunori Kajino, Shuji Matsuoka. A New CD10 Antibody Inhibits the Growth of Malignant Mesothelioma. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2021. 40. 1. 21-27
Yoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, Shigehisa Kitano, Katsuya Nakai, Ritsuko Sasaki, Aiko Kurisaki-Arakawa, Atsushi Arakawa, Naomi Otsuji, Shuji Matsuoka, et al. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Cancer Science. 2020. 111. 7. 2647-2654
Yoshitomo Hamano, Fuyu Ito, Osamu Suzuki, Minako Koura, Shuji Matsuoka, Toshiyuki Kobayashi, Yoshinobu Sugitani, Nadila Wali, Ai Koyanagi, Okio Hino, et al. Vasculitis and crescentic glomerulonephritis in a newly established congenic mouse strain derived from ANCA-associated vasculitis-prone SCG/Kj mice. Autoimmunity. 2019. 52. 5-6. 208-219
Ryo Hatano, Taketo Yamada, Hiroko Madokoro, Haruna Otsuka, Eriko Komiya, Takumi Itoh, Yuka Narita, Satoshi Iwata, Hiroto Yamazaki, Shuji Matsuoka, et al. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens. PLOS ONE. 2019. 14. 6. e0218330-e0218330
Takumi Itoh, Ryo Hatano, Eriko Komiya, Haruna Otsuka, Yuka Narita, Thomas M. Aune, Nam H. Dang, Shuji Matsuoka, Hisashi Naito, Mitsutoshi Tominaga, et al. Biological Effects of IL-26 on T Cell-Mediated Skin Inflammation, Including Psoriasis. Journal of Investigative Dermatology. 2019. 139. 4. 878-889

ｍore...

MISC (31)：

豊田釈子, 松岡周二, 小松則夫, 八木田秀雄. アナコポーシスを誘導するモノクローナル抗体は血液癌に有望な治療手段である(Anapocosis-inducing mAbs may be promising therapeutic device for hematological cancer). 日本癌学会総会記事. 2018. 77回. 51-51
Matsuoka Shuji, Mizutani Natsuko, Yagita Hideo, Takamatsu Hiroyuki, Hino Okio. Cell death of activated lymphocytes and lymphoma/leukemia cells induced by MHC class I and II mAb. (Anapocosis). CANCER SCIENCE. 2018. 109. 546
松岡周二, 水谷奈津子, 八木田秀雄, 高松博幸, 樋野興夫. 抗体医薬開発の新しい戦略抗MHC class I,II抗体による活性化リンパ球と悪性リンパ腫、ATL細胞、患者DLBCL細胞のアナポコーシス細胞死. 日本癌学会総会記事. 2017. 76回. S11-6
水谷奈津子, 松岡周二, 梶野一徳, 脇屋緑, 樋野興夫. 悪性中皮腫に対する新規抗体作製. 日本癌学会総会記事. 2016. 75回. P-2395
松岡周二, 石井保之, 高松博幸, 長谷川寛雄, 水谷奈津子, 八木田秀雄, 樋野興夫. 抗汎MHCモノクローナル抗体はリンパ腫やATLの細胞株だけでなく、患者の白血化したリンパ腫細胞もアナポコーシスで殺した. 日本癌学会総会記事. 2016. 75回. E-3057

ｍore...

Education (3)：

- 1993 The University of Tokyo
1979 - 1985 Yamaguchi University School of Medicine
1977 - 1979 Yokohama National University Faculty of Engineering Department of Production Facility Design

Professional career (2)：

(BLANK) (The University of Tokyo)
(BLANK) (Yokohama National University)

Work history (6)：

2018/04 - 現在 Juntendo University School of Medicine Department of Immunological Diagnosis Project Associate Professor
2006/04 - 2018/03 Juntendo University School of Medicine Department of Pathology and Oncology Assistant Professor
1996/04 - 2006/03 Juntendo University School of Medicine Department of Pathology (2) Assistant Professor
1996 - 2001 Juntendo Sch, of Med, Research Assistance.
1993 - 1996 ラホヤ免疫アレルギ研究所研究員

Show all

Association Membership(s) (3)：

Japanese Society for Immunology , The Japanese Society for Cell Death Research , Japanese Cancer Association

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page